What are the targets of axitinib (Inlida) and its role in treatment?

Axitinib (Axitinib) is an oral small molecule targeted drug mainly used to treat advanced or metastatic renal cell carcinoma (RCC). Its core mechanism of action is to inhibit the vascular endothelial growth factor receptor (VEGFR) family, including VEGFR-1, VEGFR-2 and VEGFR-3. VEGFRPlays a key role in the process of tumor angiogenesis. By blocking these receptors, axitinib can inhibit the formation of new blood vessels, thereby reducing tumor blood supply and limiting tumor growth and metastasis.

In addition toVEGFR, axitinib also has certain inhibitory effects on some other tyrosine kinase receptors, but its high selectivity makes its impact on non-target tissues relatively limited. This high selectivity helps to reduce the risk of systemic side effects while ensuring anti-tumor efficacy, making it easier for patients to tolerate long-term treatment. Clinical data show that axitinib can significantly prolong progression-free survival (PFS) and improve disease control rate in patients with advanced renal cancer who have failed other previous treatments.

In treatment practice, axitinib not only limits the growth of the tumor itself, but also indirectly affects the tumor microenvironment by inhibiting tumor angiogenesis. When a tumor lacks sufficient blood supply, its cell metabolism and nutrient acquisition capacity decreases, thereby increasing the possibility of cell apoptosis. In addition, vascular inhibition can also improve immune cell infiltration and make tumors better respond to immunotherapy. This is also the scientific basis for axitinib to be often used in combination with immune checkpoint inhibitors.

In general, axitinib achieves effective blocking of tumor angiogenesis by precisely acting on VEGFR and related targets, and is an important targeted drug for the treatment of advanced renal cell carcinoma. Its clear mechanism of action and high target selectivity make it not only effective in clinical applications, but also well tolerated by patients, providing reliable treatment options and new hope for patients with advanced renal cancer.

Reference materials:https://www.drugs.com/